122MO Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1
Titel:
122MO Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1
Auteur:
Reck, M. Ciuleanu, T.E. Pluzanski, A. Lee, J.S. Bernabe Caro, R. Linardou, H. Burgers, J. Gallardo, C. Nishio, M. Peters, S. Paz-Ares, L.G. Hellmann, M.D. Borghaei, H. Ramalingam, S.S. O’Byrne, K. Hu, N. Bushong, J. Eccles, L. Grootendorst, D. Brahmer, J.R.